Icon PLC

CPHI Middle East, held in Saudi Arabia from December 10-12, 2024, aims to accelerate the establishment of a robust domestic manufacturing base. The event, under the patronage of the Saudi Ministry of Health, will feature over 150 experts, including a Ministerial Panel outlining the Kingdom's biopharma strategy. With over 400 companies exhibiting, including 80 from India, the event seeks to develop partnerships and supply ecosystems, aligning with Saudi Arabia's goal to produce 40% of its drug needs domestically by 2030.

The US clinical trials market is projected to grow by USD 5 billion from 2024-2028, driven by increased drug trials and technological advancements, though rising costs pose a challenge.

The global HIV clinical trials market is projected to grow from USD 1.30 billion in 2024 to USD 2.42 billion by 2034, at a CAGR of 6.4%. Key factors driving growth include increasing HIV infections, R&D investments, drug approvals, and HIV vaccine trials. Phase I trials held the largest revenue share in 2024, while the Asia Pacific region is expected to register the fastest growth. Major companies like Gilead Sciences and Janssen Global Services are significant contributors to the market.

The global Small Molecule Drug Discovery Market is growing due to outsourcing to CROs and increased R&D in the pharmaceutical industry. The market is expected to reach $106.77 billion by 2031 from $50.93 billion in 2023 at a CAGR of 9.7%. Key players include Bristol-Myers Squibb, Merck, GSK, Boehringer Ingelheim, Thermo Fisher Scientific, ICON, Danaher, Charles River Laboratories, Oncodesign Services, and Revvity Inc.

The eCOA, eSource, and clinical trials market is projected to grow from $44.85 billion in 2023 to $67.33 billion in 2028 at a CAGR of 8.3%, driven by technological advancements, increased demand for clinical trials, and adoption of patient-centric approaches.

The bioanalytical testing services market, valued at USD 4.2 Billion in 2022, is projected to reach USD 11.4 Billion by 2032, driven by pharmaceutical R&D and regulatory compliance. North America leads, while Asia-Pacific shows significant growth. Key trends include collaborations, technological advancements, and automation in testing processes.

The U.S. clinical trials market is projected to reach $57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominated in 2024, with oncology holding the largest revenue share. Key players include IQVIA, Fortrea Inc., PAREXEL, and Thermo Fisher Scientific.

The U.S. clinical trials market is projected to reach $57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominated in 2024, with oncology leading by indication. Key players include IQVIA, Fortrea Inc., and PAREXEL International Corporation.

The Biotechnology & Pharmaceutical Services Outsourcing Market report forecasts growth through strategic insights, market trends, and detailed analysis of drivers, restraints, opportunities, and challenges. Key players include Parexel, IQVIA, Lachman, GMP Pharmaceuticals, and others. The market is segmented by services and end-users, with regions including North America, Europe, Asia-Pacific, Middle East & Africa, and South America. The study aims to provide a comprehensive overview, value chain analysis, and competitive landscape to identify growth opportunities.